Pharmaceutical Business review

Valeant Pharmaceuticals sells certain European business operations to Meda

Valeant has received approximately $425 million in cash from Meda at closing, which is subject to certain closing adjustments.

Goldman, Sachs & Co served as financial advisor to Valeant and Skadden, Arps, Slate, Meagher & Flom provided legal advice.